FRANKLIN, Mass. - Arthrosurface, Inc., the developer of less-invasive joint resurfacing systems, has received approval from the U.S. FDA to begin its pivotal investigation for its line of focal knee resurfacing implants. Arthrosurface has been evaluating the safety and efficacy of its HemiCAP® implants for focal femoral condyle defects under an ongoing U.S. FDA IDE investigation.

With the HemiCAP® knee implant, the company is targeting a subgroup of knee patients, typically between the ages of 40 and 60 years, who have focal condylar defects and are likely to undergo knee replacement surgery in the future. HemiCAP® resurfacing is intended to bridge the gap between biologic procedures and conventional joint replacement. Arthrosurface's minimally invasive resurfacing system allows for preservation of healthy tissue and joint structures by limiting treatment to localized defects using a shallow inlay implant that is matched to the patient's own unique joint surface anatomy.

With this Phase III study approval, the company is moving one step closer to bringing this new treatment option to U.S. patients.

Based on the same platform technology, the company also globally markets products in other major joints and extremities.

For more information go to (http://www.arthrosurface.com)

More Voices